Aspirin May Fight Cancer — But Not for the Reason You Think

Key Takeaways

• 100 million cell measurements enable “cell‑state reversal” drug ranking.
• Salicylate outperforms aspirin in reverting colon cancer gene signatures.
• AMPK activation by salicylate degrades c‑MYC and triggers miR‑34 tumor suppression.
• ALASCCA trial shows low‑dose aspirin halves recurrence in PI3K‑mutated colorectal cancer.
• NCCN now recommends genetic testing and three‑year aspirin therapy post‑surgery.

Pulse Analysis

The unprecedented scale of the Tahoe Therapeutics dataset—100 million single‑cell readouts across 1,100 compounds—lets scientists move beyond the traditional "kill‑the‑cell" assay. By quantifying how each drug nudges a cancer cell’s gene‑expression profile toward a healthy state, the platform validates known targeted therapies and uncovers hidden candidates, reshaping early‑stage drug discovery for oncology.

At the heart of the surprise is salicylate, the core of aspirin stripped of its acetyl group. Unlike aspirin’s COX‑inhibiting anti‑inflammatory action, salicylate activates the cellular energy sensor AMPK, which in turn tags the oncogenic driver c‑MYC for destruction. This cascade frees NRF2 to launch miR‑34 microRNAs, re‑engaging the body’s innate tumor‑suppression network without relying on p53. The mechanism explains why low‑dose aspirin, which is rapidly converted to salicylate in the bloodstream, delivered a 50% reduction in three‑year recurrence for patients with PI3K‑mutated colorectal tumors in the landmark ALASCCA trial.

Clinically, the data have immediate impact. The NCCN now advises routine PIK3CA testing for stage II‑III colon cancer and recommends a three‑year course of low‑dose aspirin for mutation‑positive patients—a rare instance of a century‑old, inexpensive drug earning a place in precision oncology. Beyond colorectal cancer, the AMPK‑c‑MYC‑miR‑34 axis suggests broader applicability across tumor types, spurring new trials and potential combination strategies with immunotherapy. As researchers continue to mine the massive cell‑state dataset, salicylate may become a template for repurposing other legacy compounds into targeted cancer‑preventive agents.